StockData
CalciMedica, Inc. logo

CalciMedica, Inc. (CALC) company profile

CALCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 2/30
$1.21−0.01 (-0.82%)

Close on Nov 13, 2026Market cap $8.34MP/E –Yield –

About CalciMedica

Pharmaceutical Preparations, SIC 2834

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. The company concentrates on calcium release-activated calcium (CRAC) channel inhibitors, designed to modulate inflammatory signaling and protect tissues from calcium-mediated injury. Its lead product candidate, Auxora (containing the active compound zegocractin), is an intravenously administered small molecule evaluated in clinical studies for acute critical care conditions, including acute pancreatitis, severe COVID-19 pneumonia, pediatric asparaginase-induced pancreatic toxicity, and acute kidney injury. In addition, the company is conducting nonclinical development on CM5480, targeting pulmonary arterial hypertension. CalciMedica operates in a single operating segment focused on research and drug development, serving patients suffering from acute and chronic inflammatory disorders.

The company conducts its clinical and nonclinical development operations across the United States and internationally, having conducted clinical trial activity in India. CalciMedica maintains its principal executive offices in La Jolla, California.

Summary of the business section of CalciMedica's latest annual report, written by StockData.

Company profile

Company

Legal name
CalciMedica, Inc.
Headquarters
La Jolla, CA
Address
505 Coast Boulevard South, Suite 307 92037
Phone
(858) 952-5500
Employees
16, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Baker Tilly US, LLP, San Diego, CaliforniaMarch 3, 2026

Stock & identifiers

Ticker
CALC
Former tickers
GRAY until Mar 22, 2023
Exchange
Nasdaq
IPO date
Sep 25, 2020
Shares outstanding
34M, Aug 5, 2026
Public float
$15.70M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-5 reverse, Aug 31, 2026
SEC CIK
1534133
CUSIP
38942Q202
ISIN
US38942Q2021
FIGI
BBG0088HHJ97
Share class FIGI
BBG0088HHJB4
EIN
45-2120079

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Eric W. RobertsCHIEF BUSINESS OFFICER, Director1,250,466
A. Rachel LehenyCHIEF EXECUTIVE OFFICER, Director1,061,481
Sudarshan HebbarChief Medical Officer186,025
Kenneth A. StaudermanChief Scientific Officer12,944
Stephen BardinChief Financial Officer43,000
Michael J. DunnPresident and COO11,761
Frederic GuerardDirector111,110
Allan ShawDirector–
Alan GlicklichDirector–
Robert N. WilsonDirector1,604,650
Evgeny ZaytsevDirector2,113,513
Fred A. MiddletonDirector2,700,834

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$895.41K$2.44M$733.44K$230–
FY2024$1.66M$1.46M$1.32M$124–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsOtherTotalvs. prior year
A. Rachel Leheny, Ph.D.
Chief Executive Officer
$427.35K$464.49K$3.58K$895.41K-46%
Sudarshan Hebbar, M.D.
Chief Medical Officer
$427.35K$332.49K$3.48K$763.32K-43%
Eric W. Roberts
Vice Chairman and Chief Business Officer
$400.53K$299.72K$3.31K$703.56K-46%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 25, 2020
Offer price
$16.00
Securities offered
5,625,000
Gross proceeds
$90.00M
Exchange
Nasdaq
First trading day
Sep 25, 2020
Lock-up ends (est.)
Mar 24, 2021

“The initial public offering price is $16.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 16 full-time employees, eight of whom were primarily engaged in research and development activities.”

Corporate history

Events identified from SEC filings

DateEventDetails
Mar 18, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 6, 2025Auditor changeChange in certifying accountant (8-K Item 4.01)
Apr 10, 2024Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 13, 2023ListingRegistration of securities on an exchange (Form 8-A)
May 5, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 22, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 22, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 15, 2023Name changeName changed from GRAYBUG VISION, INC. to CalciMedica, Inc. /DE/
Feb 9, 2023Merger voteDefinitive merger proxy statement
Dec 28, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 21, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 25, 2020IPOInitial public offering priced (424B4 prospectus)
Sep 21, 2020ListingRegistration of securities on an exchange (Form 8-A)
May 13, 2016Name changeName changed from GRAYBUG, Inc. to GRAYBUG VISION, INC.
Oct 7, 2014Name changeName changed from GRAYBUG LLC to GRAYBUG, Inc.

See a number that looks wrong?